BiCKI: An Optimized Anti-PD1 Bispecific Platform In Particular For Immunocytokine Such As With IL-7.

Time: 5:15 pm
day: Day Two


  • The BiCKI monovalent anti-PD1 platform has been optimized for manufacturing and pharmacokinetics of innovative bispecific fusion proteins
  • Key roles of the valency and affinity of fused cytokines
  • Significant preclinical efficacy of anti-PD1/IL-7 bispecific in syngeneic immunocompetent or humanized mice models